Algernon Pharmaceuticals Inc.
CSE: AGN, OTCQB: AGNPF, FFT: AGW
Company Overview
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
-$0.11
Diluted EPS (ttm)
Management Team
Mr. Christopher J. Moreau
CEO & Director
Mr. Michael S. M. Sadhra CA, CPA
CFO & Director
Dr. Christopher Bryan Ph.D.
VP of Research & Operations
Dr. Ahmad Khalil
Chief Medical Officer
Key Highlights
Market Capitalization
$0
Shares Outstanding
0
Shares Short (% of Float)
72,357 (0%)
Insider Ownership
5%